surmount 1 tirzepatide SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, SURMOUNT-5: Tirzepatide shows superior weight
Description
Smaller injection volumes mean less subcutaneous fluid, reduced injection site reactions, and faster absorption
You are most likely to experience these issues during the initial phase of treatment or immediately after a dose increase the period when your body is adjusting to a higher level of the medication
What is available today may not be available next month
Patients who eat larger meals or consume high-fat foods right before or after injection often report worse nausea
The titration schedule is different
